Targets and Biomarkers in Cutaneous Lymphoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1704

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Dermatology and Venerolgy, Helios Klinikum Krefeld, Krefeld, Germany
2. Institute of Molecular Medicine, Medical School Hamburg, Hamburg, Germany
Interests: dermato-oncology; cutaneous lymphoma; malignant melanoma; dermatopathology; clinical trials; targeted therapies; autoimmune diseases
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Dermatology, Venereology and Allergology, Charité-Universitätsmedizin Berlin, Berlin, Germany
Interests: cutaneous lymphoma; dermato-oncology

Special Issue Information

Dear Colleagues,

Cutaneous lymphomas are clinically and biologically heterogeneous and have overlapping diagnostic features. With the advance of new technologies and the application of efficient and feasible detection platforms, an unprecedented number of novel biomarkers have been discovered or are under investigation at the genetic, epigenetic, and protein levels and the tumor microenvironment. These biomarkers have enabled new clinical and pathological insights into the mechanisms underlying lymphomagenesis and have also facilitated improvements in the potential of personalized therapy for cutaneous lymphoma patients. However, integrating these biomarkers into clinical practice effectively and precisely in daily practice is challenging. More in-depth studies are required to further validate these novel biomarkers and to assess other parameters that can affect the reproducibility of these biomarkers, such as the selection of detection methods, biological reagents, and interpretation of data.

Despite these challenges, there are many reasons to be optimistic that novel biomarkers will facilitate better algorithms and strategies as we enter a new era of precision medicine to better refine diagnosis, prognostication, and rational treatment design for patients with lymphomas.

This Special Issue welcomes works regarding biomarkers related to alterations in cutaneous lymphomas at the genetic, epigenetic, protein levels, and the tumor microenvironment.

Prof. Dr. Chalid Assaf
Dr. Gabor Dobos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cutaneous T cell lymphoma (CTCL)
  • biomarker
  • targets
  • diagnostics
  • personalized medicine
  • mycosis fungoides
  • Sézary syndrome
  • genetics
  • epigenetics
  • tumor microenvironment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 1368 KiB  
Systematic Review
JAK Inhibitors in Cutaneous T-Cell Lymphoma: Friend or Foe? A Systematic Review of the Published Literature
by Seyed Mohammad Vahabi, Saeed Bahramian, Farzad Esmaeili, Bardia Danaei, Yasamin Kalantari, Patrick Fazeli, Sara Sadeghi, Nima Hajizadeh, Chalid Assaf and Ifa Etesami
Cancers 2024, 16(5), 861; https://doi.org/10.3390/cancers16050861 - 21 Feb 2024
Viewed by 1538
Abstract
Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for [...] Read more.
Cutaneous T-cell lymphomas (CTCLs) are a group of lymphoid neoplasms with high relapse rates and no curative treatment other than allogeneic stem cell transplantation (allo-SCT). CTCL is significantly influenced by disruption of JAK/STAT signaling. Therefore, Janus kinase (JAK) inhibitors may be promising for CTCL treatment. This study is a systematic review aiming to investigate the role of JAK inhibitors in the treatment of CTCL, including their efficacy and safety. Out of 438 initially searched articles, we present 13 eligible ones. The overall response rate (ORR) in the treatment with JAK inhibitors in clinical trials was 11–35%, although different subtypes of CTCL showed different ORRs. Mycosis fungoides showed an ORR of 14–45%, while subcutaneous-panniculitis-like T-cell lymphoma (SPTCL) displayed an ORR ranging from 75% to 100%. Five cases were reported having a relapse/incident of CTCL after using JAK inhibitors; of these, three cases were de novo CTCLs in patients under treatment with a JAK inhibitor due to refractory arthritis, and two cases were relapsed disease after graft-versus-host disease treatment following allo-SCT. In conclusion, using JAK inhibitors for CTCL treatment seems promising with acceptable side effects, especially in patients with SPTCL. Some biomarkers, like pS6, showed an association with better responses. Caution should be taken when treating patients with an underlying autoimmune disease and prior immunosuppression. Full article
(This article belongs to the Special Issue Targets and Biomarkers in Cutaneous Lymphoma)
Show Figures

Figure 1

Back to TopTop